Wells Fargo & Company Has Lowered Expectations for Omnicell (NASDAQ:OMCL) Stock Price

Omnicell (NASDAQ:OMCL) had its price objective cut by Wells Fargo & Company from $38.00 to $31.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other brokerages also recently commented on OMCL. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, May 3rd. Benchmark restated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. lowered their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $45.83.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $25.88 on Wednesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The stock has a market cap of $1.21 billion, a PE ratio of 95.86, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The stock has a fifty day moving average of $32.28 and a 200-day moving average of $39.96.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business had revenue of $269.67 million during the quarter, compared to analyst estimates of $260.18 million. During the same quarter in the previous year, the firm earned $0.03 EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities research analysts anticipate that Omnicell will post 1.09 earnings per share for the current year.

Institutional Trading of Omnicell

A number of hedge funds have recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after acquiring an additional 273 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in Omnicell in the fourth quarter worth $37,000. Van ECK Associates Corp boosted its position in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the period. Headlands Technologies LLC bought a new position in shares of Omnicell during the fourth quarter valued at about $53,000. Finally, First Horizon Advisors Inc. increased its holdings in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after buying an additional 355 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.